Second-generation long-acting injections anti-psychotics improve executive functions in patients with schizophrenia: a 12-month real-world study

International Journal of Psychiatry in Clinical Practice
Fabio MaglioccoPasquale De Fazio

Abstract

Background: The main purpose of this study was to assess possible modifications of cognitive performance among schizophrenia patients treated with long-acting injectable antipsychotics (LAIs) of second generation anti-psychotics (SGAs). Our hypothesis is that the shift from the oral formulation to the LAI formulation of SGAs drugs improves the cognitive performance. The secondary objective was to carry out a head to head comparison of two different SGA-LAI treatments [i.e., 1-month Paliperidone Palmitate (PP1M), monthly Aripiprazole (Ari-LAI)] in our study with an independent and real-world setting.Methods: The sample comprised 32 participants who were consecutively recruited over 12 months. Seventeen patients treated with Ari-LAI and 10 treated with PP1M completed psychopathological, neuropsychological and functional assessments. Group differences were explored through chi-squared and t-tests, as appropriate. GLM Repeated Measures were used to study variations of cognitive performance along 12 months and to test differences between drugs.Results: We found an effect of time on the outcomes investigated but this did not depend on the type of LAI used.Conclusions: In comparison with the previous oral treatment with SGAs, patients...Continue Reading

References

Jan 1, 1987·Schizophrenia Bulletin·S R KayL A Opler
Dec 1, 1995·Quality of Life Research : an International Journal of Quality of Life Aspects of Treatment, Care and Rehabilitation·R A BerzonH H Tilson
Feb 7, 2001·The American Journal of Psychiatry·P D Harvey, R S Keefe
Mar 3, 2005·The American Journal of Psychiatry·Nancy C AndreasenDaniel R Weinberger
May 28, 2010·The British Journal of Psychiatry. Supplement·Linda Waddell, Mark Taylor
Jul 23, 2011·The International Journal of Neuropsychopharmacology·W Wolfgang FleischhackerMarielle Eerdekens
Oct 22, 2013·JAMA : the Journal of the American Medical Association·UNKNOWN World Medical Association
Nov 2, 2014·Therapeutic Advances in Psychopharmacology·Sofia BrissosVicent Balanzá-Martinez
Oct 4, 2015·Schizophrenia Research·Andreas SchreinerLudger Hargarter
Jan 19, 2016·Lancet·Michael J OwenPreben B Mortensen
Mar 12, 2016·Current Opinion in Psychiatry·Robin EmsleyLebogang Phahladira
May 5, 2016·Neuropsychiatric Disease and Treatment·Cristiana MontemagniPaola Rocca
Jan 1, 2015·Nature Reviews. Disease Primers·René S KahnThomas R Insel
Oct 13, 2016·The Journal of Clinical Psychiatry·Christoph U CorrellJohn M Kane
Mar 9, 2017·International Journal of Molecular Sciences·Hikaru HoriHirotaka Tominaga

❮ Previous
Next ❯

Citations

Mar 30, 2021·Expert Opinion on Drug Safety·Renato de FilippisMaria Rosaria Anna Muscatello
Jul 9, 2021·Neuropsychiatric Disease and Treatment·Renato de FilippisPasquale De Fazio

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antipsychotic Drugs

Antipsychotic drugs are a class of medication primarily used to manage psychosis (including delusions, hallucinations, paranoia or disordered thought), principally in schizophrenia and bipolar disorder. Discover the latest research on antipsychotic drugs here

Related Papers

Clinical Psychopharmacology and Neuroscience : the Official Scientific Journal of the Korean College of Neuropsychopharmacology
Hyun-Ghang Jeong, Moon-Soo Lee
The British Journal of Psychiatry. Supplement
W Wolfgang Fleischhacker
© 2021 Meta ULC. All rights reserved